Domatinostat (formerly 4SC-202) is a novel, potent, and orally bioavailable benzamide-based Class I HDAC inhibitor with potential anticancer activity.

PCI-34051 is a novel, potent and specific inhibitor of histone deacetylase 8 (HDAC8 ) with potential anticancer activity.

M344 (D-237; MS-344), an amide analogue of Trichostatin A, is a novel and potent pan-HDAC (histone deacetylase) inhibitor with potential anticancer activity.

Pracinostat (formerly SB-939) is a novel, potent and orally bioavailable pan-HDAC (histone deacetylase) inhibitor with potential anticancer activity.

TMP269 is a novel, potent, selective inhibitor of class IIa HDAC(4/5/7/9) with potential anticancer activity.

CUDC-101 is a novel, potent and multi-targeted histone deacetylase (HDAC) inhibitor with potential anticancer activity. It also inhibits EGFR and HER2 with IC50s of 4.4 nM, 2.4 nM, and 15.7 nM.

Tubastatin A (TubA, AG-CR13900), a tubacin derivative, is a potent and selective HDAC6 (Histone deacetylase 6) inhibitor (IC50 = 15 nM in a cell-free assay) with potential anticancer and anti-inflammatory activity.

BRD73954 (BRD-73954) is a novel, potent and dual inhibitor of histone deacetylase 6 (HDAC6) and HDAC8 with potential anticancer activity.

Belinostat (formerly PXD-101; PX-105684; NSC-726630; trade name Beleodaq) is a novel, potent and selective HDAC (histone deacetylase) inhibitor with high anticancer activity.

BRD3308 is a novel and potent inhibitor of HDAC3